<Anchor> While

clinical trials for vaccines have begun in Korea, I hear that there has been some progress in foreign countries. The most curious thing right now is when this vaccine is being developed and when can we get it?

A medical journalist Cho Dong-chan will solve that question.

<Reporter> The

US research team announced that 45 healthy people were given twice a dose of the American Modern Screw vaccine at 28-day intervals to produce a neutralizing antibody against the virus.

There were no serious side effects other than hives and fatigue.

The International Vaccine Research Institute evaluated that it was meaningful that the amount of neutralizing antibodies produced after being vaccinated was higher than the average value of neutralizing antibodies of the Corona 19 cure.

However, he pointed out that it should be watched whether it will actually work and how long it will last.

Other studies have shown that even in the case of cured people, neutralizing antibodies last only about three months.

[Hong Ki-jong/Editor of the Korean Society of Vaccine Society: Overall, there are many antibodies that are not related to neutralizing antibodies, so more research is needed to see if they are actually effective.]

Current status of major vaccine development in the world.


In addition to the DNA vaccine from Innovis of the United States, which entered clinical trials today (15th), the vaccine from the American modern company using viral RNA, the vaccine from Oxford University of England using the chimpanzee adenovirus, and the protein recombinant method from Nova Vax of the United States The back is getting attention.

In order for these vaccine candidates to be successful, they must prove whether they can have a consistent effect not only on the effectiveness and safety, but also on the Corona 19 mutation, and whether the mass supply is possible when the production starts.

Currently, it is difficult to know which vaccine will succeed first.

The International Vaccine Research Institute advises that the Korean government should hurry up clinical trials for various vaccines being developed at home and abroad.

This is because the vaccine can be administered immediately if successful.

Starting with the US DNA vaccine today, domestic clinical trials for the Korean DNA vaccine next month and the Korean recombinant protein vaccine will begin in September.


When is it possible to inoculate the public?

Technically, it may be possible this year, but there are many prospects that it will actually move to next year to ensure sufficient safety.

(Video coverage: Yongwoo Kim, Video editing: Hojin Kim)